Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.